July 31 (Reuters) - Immutep Ltd IMM.AX :
* GETS APPROVAL FOR INVESTIGATIONAL NEW DRUG APPLICATION BY U.S. FDA FOR EFTILAGIMOD ALPHA A LAG-3IG FUSION PROTEIN
* APPROVAL ALLOWS COMPANY TO INITIATE TACTI-002 PHASE II CLINICAL STUDY IN U.S
July 31 (Reuters) - Immutep Ltd IMM.AX :
* GETS APPROVAL FOR INVESTIGATIONAL NEW DRUG APPLICATION BY U.S. FDA FOR EFTILAGIMOD ALPHA A LAG-3IG FUSION PROTEIN
* APPROVAL ALLOWS COMPANY TO INITIATE TACTI-002 PHASE II CLINICAL STUDY IN U.S